Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.37 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.37 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 11/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3323466 | 1.00 | KDM1A (0.37) | KDM1AKDM1BRCOR1HTR2CHTR2B | |
| SCHEMBL3321846 | 1.00 | KDM1A (0.37) | KDM1AKDM1BRCOR1HTR2CHTR2B | |
| SCHEMBL2317663 | 0.87 | TRPV1 (0.41) | KDM1AKDM1BRCOR1HTR2CHTR2B | |
| SCHEMBL2317667 | 0.87 | TRPV1 (0.41) | KDM1AKDM1BRCOR1HTR2CHTR2B | |
| SCHEMBL3323061 | 0.83 | TRPV1 (0.40) | KDM1AKDM1BRCOR1HTR2CHTR2B | |
| SCHEMBL3323057 | 0.83 | TRPV1 (0.40) | KDM1AKDM1BRCOR1HTR2CHTR2B | |
| SCHEMBL3320421 | 0.82 | TRPM8 (0.40) | KDM1ARCOR1HTR2CHTR2BTRPV1 | |
| SCHEMBL3323531 | 0.82 | TRPV1 (0.43) | KDM1AKDM1BRCOR1HTR2CHTR2B | |
| SCHEMBL3322042 | 0.82 | TRPM8 (0.40) | KDM1ARCOR1HTR2CHTR2BTRPV1 | |
| SCHEMBL3323535 | 0.82 | TRPV1 (0.43) | KDM1AKDM1BRCOR1HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609692-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8604053-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20100137360-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137360-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | KDM1A 3338/4885KDM1B 3558/4885RCOR1 462/4885 |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | KDM1A 3414/4885KDM1B 3679/4885RCOR1 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.